Screener
Artiva Biotherapeutics, Inc. ARTV Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
FAQ
- What is Artiva Biotherapeutics, Inc.'s cash & equivalents?
- Artiva Biotherapeutics, Inc. (ARTV) reported cash & equivalents of $301.92M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s cash & equivalents changed year-over-year?
- Artiva Biotherapeutics, Inc.'s cash & equivalents increased by 943.6% year-over-year, from $28.93M to $301.92M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s cash & equivalents?
- Over 3 years (2022 to 2025), Artiva Biotherapeutics, Inc.'s cash & equivalents has grown at a -35.8% compound annual growth rate (CAGR), from $102.78M to $27.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Artiva Biotherapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude